BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region has recently accepted the New Drug Application for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.

The global breast cancer diagnostics market was valued at USD 4.49 billion in 2023 and is expected to reach over USD 9.00 billion by 2033, poised to grow at a noteworthy CAGR of 7.2% from 2024 to 2033 North America dominated the market with a revenue share of 46.00% in terms of revenue in 2023.

Scientists have long known that our brains are organized into specialized areas, each responsible for distinct tasks. The visual cortex processes what we see, for instance, while the motor cortex governs movement.

Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for VELSIPITY™.

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be highlighted during an oral presentation on Friday, May 31, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill.

Olympus announced data showing that the use of Narrow Band Imaging technology with patients with non-muscle invasive bladder cancer led to 37% less likelihood of recurrence over 12-35 months.

According to nova one advisor to the U.S. cell and gene therapy manufacturing market size was valued at USD 4.10 billion in 2023 and is projected to reach USD 45.46 billion by 2033, growing at a CAGR of 27.2% from 2024 to 2033.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024.